"I have consistently expressed my concern to the committee that I do not think requiring a reduction in price for a streamlined cost pathway is an appropriate way forward," said Medicines Australia chief executive Liz de Somer.
'If it is necessary for me to formally dissent in the final report, I will do so'
February 1, 2024 Latest NewsBioPharmaBioPharmaDispatch ExecutiveNews of the Day![](https://e76bb9fd1f54a7a912eb-40f6ec802f763655ee14c32dfe77820e.ssl.cf4.rackcdn.com/ec973269ee0e99bad405e43c67132078.png)
Latest Video
New Stories
-
The 'Week in Review' Podcast - 26 July
July 26, 2024 - - Podcast -
'We approached stakeholders that were highly engaged with the HTA review process'
July 26, 2024 - - Latest News -
Preaching transparency and not practising it is the worst possible look
July 26, 2024 - - Latest News -
Cartherics announces new licensing agreement for innovative cardiac cell therapy
July 25, 2024 - - Latest News -
New large study shows vaccination halves the risk of patients suffering Long-COVID
July 25, 2024 - - Latest News -
These layered levels of privilege are not making decision-making or the system better
July 25, 2024 - - Latest News -
Telix completes significant raise that could be used for acquisitions
July 25, 2024 - - Latest News